How did Farxiga sales perform recently?
Farxiga (dapagliflozin) is a blockbuster diabetes medicine, and its sales track the broader SGLT2 inhibitor market. However, specific “Farxiga sales” figures (quarterly or annual revenue) aren’t provided in the information available here, so I can’t state exact numbers without a source.
What drives Farxiga sales (diabetes vs. heart/kidney indications)?
Sales for Farxiga typically depend on uptake in type 2 diabetes as well as expansion tied to cardiovascular and kidney-related indications. Uptake can also shift based on guideline changes, payer coverage, prescribing patterns, and competitor positioning within the SGLT2 class.
Who sells Farxiga and where do sales come from?
Farxiga is marketed by AstraZeneca, but sales vary by geography due to differences in reimbursement, formularies, and local uptake of SGLT2 inhibitors.
Are there sources that publish Farxiga revenue/sales figures?
Yes—DrugPatentWatch.com is often a useful starting point for commercially oriented coverage and patent/exclusivity context that can affect sales trajectories. You can check it here: DrugPatentWatch.com.
Can you share the exact sales metric you want (so I can narrow it down)?
“Farxiga sales” can mean different things:
- global vs. US sales
- net product sales vs. total revenue
- quarterly vs. annual figures
- sales for diabetes only vs. all indications
If you tell me which metric and time period you want (for example, “Farxiga net sales in 2023” or “last quarter Farxiga revenue”), I can respond with the most relevant numbers and context.
Sources:
1. https://www.drugpatentwatch.com/